SCHEMBL16632742

SCHEMBL16632742

N#Cc1cc2c(Oc3ccc(F)cc3O)cccc2o1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.38
TRPA1 O75762 1/20 0.34
MAPT P10636 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
P4HB P07237 1/20 0.32
AR P10275 2/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32
GABRA3 P34903 1/20 0.32
GABRA2 P47869 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16632479 0.87 CYP2A6 (0.45) CYP2A6MAPTCYP3A4CYP2C9CYP2C19
SCHEMBL16632556 0.86 TTR (0.46) CYP2A6MAPTSLC6A2SLC6A3
SCHEMBL16632749 0.84 MAPT (0.36) MAPTCYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL16632454 0.84 AR (0.41) CYP2A6L3MBTL1AR
SCHEMBL16632984 0.76 CYP2A6 (0.45) CYP2A6MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL3484201 0.73 AR (0.39) CYP2A6MAPTARKDM4ESLC6A2
SCHEMBL5584528 0.73 CYP2A6 (0.50) CYP2A6MAPTCYP1A2CYP3A4CYP2C9
SCHEMBL16632452 0.73 P4HB (0.39) P4HBARSLC6A2SLC6A3
SCHEMBL16632723 0.72 SLC6A4 (0.49) MAPTARSLC6A2SLC6A3
SCHEMBL5606502 0.72 AR (0.46) ARPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9382245-B2 Compounds and methods for treating HIV infections YALE UNIVERSITY (US) 2016-07-05 US disclosed
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105351-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTIONS POLM, POLRMT, DHFR CYP2A6 785/4885TRPA1 4853/4885MAPT 1046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.